Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Immucell Corp as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- −3 vs. Q2 2022
- Shares held
- 971.4K
- −9.57K (−1.0%) vs. Q2 2022
- Total value
- $7.26M
- −$1.27M (−14.9%) vs. Q2 2022
- New holders
- 0
- 7 more added
- Sold out
- 3
- 5 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ICCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.4M |
| Q1 2026 | 27 | $8.67M |
| Q4 2025 | 26 | $7.87M |
| Q3 2025 | 27 | $8.08M |
| Q2 2025 | 25 | $9.00M |
| Q1 2025 | 27 | $5.79M |
| Q4 2024 | 27 | $6.21M |
| Q3 2024 | 22 | $4.27M |
| Q2 2024 | 28 | $5.56M |
| Q1 2024 | 25 | $5.39M |
| Q4 2023 | 28 | $5.31M |
| Q3 2023 | 30 | $5.47M |
| Q2 2023 | 31 | $5.32M |
| Q1 2023 | 30 | $5.42M |
| Q4 2022 | 26 | $5.41M |
| Q3 2022 | 26 | $7.26M |
| Q2 2022 | 29 | $8.53M |
| Q1 2022 | 27 | $9.18M |
| Q4 2021 | 29 | $7.04M |
| Q3 2021 | 28 | $8.05M |
| Q2 2021 | 28 | $7.45M |
| Q1 2021 | 28 | $7.20M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Immucell Corp; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 202,729 | $1.52M | 0.00% | −1,000−0.5% | Reduced |
| Renaissance Technologies LLC | 137,586 | $1.03M | 0.00% | −16,201−10.5% | Reduced |
| Bleichroeder LP | 101,594 | $760.0K | 0.16% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 96,426 | $721.0K | 0.01% | +2,407+2.6% | Added |
| Morgan Stanley | 74,074 | $554.0K | 0.00% | +7,300+10.9% | Added |
| Shufro Rose & Co LLC | 62,408 | $467.0K | 0.05% | −19,629−23.9% | Reduced |
| Geode Capital Management, LLC | 38,135 | $285.0K | 0.00% | +14,562+61.8% | Added |
| Perritt Capital Management Inc | 36,494 | $273.0K | 0.17% | 00.0% | Unchanged |
| Overbrook Management Corp | 35,532 | $266.0K | 0.08% | 00.0% | Unchanged |
| Strategic Financial Services, Inc, | 31,000 | $232.0K | 0.02% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 22,579 | $169.0K | 0.00% | +1,563+7.4% | Added |
| HighTower Advisors, LLC | 21,354 | $160.0K | 0.00% | +3,000+16.3% | Added |
| Flagship Harbor Advisors, LLC | 16,230 | $121.0K | 0.01% | 00.0% | Unchanged |
| Prosperity Planning, Inc. | 16,000 | $120.0K | 0.06% | +1,000+6.7% | Added |
| Wealth Effects LLC | 15,650 | $117.0K | 0.07% | 00.0% | Unchanged |
| BlackRock Inc. | 15,272 | $114.0K | 0.00% | −405−2.6% | Reduced |
| Northern Trust Corp | 12,667 | $95.0K | 0.00% | +34+0.3% | Added |
| Minerva Advisors LLC | 11,958 | $89.0K | 0.07% | 00.0% | Unchanged |
| Essex Financial Services, Inc. | 11,000 | $82.0K | 0.01% | 00.0% | Unchanged |
| HM Payson & Co | 8,130 | $61.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 2,032 | $15.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,500 | $11.0K | 0.00% | −1,148−43.4% | Reduced |
| US Bancorp | 600 | $4.00K | 0.00% | 00.0% | Unchanged |
| Geneos Wealth Management Inc. | 244 | $1.00K | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 152 | $1.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 37 | $0 | 0.00% | 00.0% | Unchanged |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −701−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −153−100.0% | Sold out |